Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Imaging CAR T cell therapy with PSMA-targeted positron emission tomography.

Minn I, Huss DJ, Ahn HH, Chinn TM, Park A, Jones J, Brummet M, Rowe SP, Sysa-Shah P, Du Y, Levitsky HI, Pomper MG.

Sci Adv. 2019 Jul 3;5(7):eaaw5096. doi: 10.1126/sciadv.aaw5096. eCollection 2019 Jul.

2.

Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.

Kadayakkara DK, Korrer MJ, Bulte JW, Levitsky HI.

Cancer Res. 2015 Jan 1;75(1):51-61. doi: 10.1158/0008-5472.CAN-14-0820. Epub 2014 Nov 11.

3.

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.

Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, Strickland SA, Jagasia M, Savani BN, Fraser JW, Sadrzadeh H, Rajkhowa T, Ito S, Jain NA, Battiwalla M, Fathi AT, Levis MJ, Barrett AJ, Hourigan CS.

Leukemia. 2014 May;28(5):1167-70. doi: 10.1038/leu.2014.14. Epub 2014 Jan 10. No abstract available.

4.

TE-array--a high throughput tool to study transposon transcription.

Gnanakkan VP, Jaffe AE, Dai L, Fu J, Wheelan SJ, Levitsky HI, Boeke JD, Burns KH.

BMC Genomics. 2013 Dec 10;14:869. doi: 10.1186/1471-2164-14-869.

5.

Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.

Qin L, Smith BD, Tsai HL, Yaghi NK, Neela PH, Moake M, Fu J, Kasamon YL, Prince GT, Goswami M, Rosner GL, Levitsky HI, Hourigan CS.

Blood Cancer J. 2013 Sep 6;3:e145. doi: 10.1038/bcj.2013.44.

6.

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R.

J Clin Invest. 2013 Jun;123(6):2447-63. Erratum in: J Clin Invest. 2013 Nov;123(11):4980.

7.

T cell assays and MIATA: the essential minimum for maximum impact.

Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM.

Immunity. 2012 Jul 27;37(1):1-2. doi: 10.1016/j.immuni.2012.07.010. No abstract available.

8.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

9.

Evaluation of current cancer immunotherapy: hemato-oncology.

Hourigan CS, Levitsky HI.

Cancer J. 2011 Sep-Oct;17(5):309-24. doi: 10.1097/PPO.0b013e3182341fde. Review.

10.

Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.

Zhou G, Ding ZC, Fu J, Levitsky HI.

J Immunol. 2011 Feb 15;186(4):2148-55. doi: 10.4049/jimmunol.1002917. Epub 2011 Jan 17.

11.

Characterization of chronic myeloid leukemia stem cells.

Gerber JM, Qin L, Kowalski J, Smith BD, Griffin CA, Vala MS, Collector MI, Perkins B, Zahurak M, Matsui W, Gocke CD, Sharkis SJ, Levitsky HI, Jones RJ.

Am J Hematol. 2011 Jan;86(1):31-7. doi: 10.1002/ajh.21915.

12.

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.

Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM.

Cancer Immunol Immunother. 2011 Jan;60(1):15-22. doi: 10.1007/s00262-010-0940-z. Epub 2010 Nov 16.

13.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ.

Blood. 2010 Apr 22;115(16):3224-30. doi: 10.1182/blood-2009-11-251595. Epub 2010 Feb 2.

14.

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI.

Clin Cancer Res. 2010 Jan 1;16(1):338-47. doi: 10.1158/1078-0432.CCR-09-2046.

15.

"MIATA"-minimal information about T cell assays.

Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM.

Immunity. 2009 Oct 16;31(4):527-8. doi: 10.1016/j.immuni.2009.09.007.

16.

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).

Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, Alyea EP, Stone RM, Damon LE, Linker CA, Maslyar DJ, Hege KM.

Blood. 2009 Aug 27;114(9):1736-45. doi: 10.1182/blood-2009-02-205278. Epub 2009 Jun 25.

17.

Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.

Bohana-Kashtan O, Morisot S, Hildreth R, Brayton C, Levitsky HI, Civin CI.

J Immunol. 2009 Jul 1;183(1):696-705. doi: 10.4049/jimmunol.0800561. Epub 2009 Jun 17.

18.

Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes.

Long CM, van Laarhoven HW, Bulte JW, Levitsky HI.

Cancer Res. 2009 Apr 1;69(7):3180-7. doi: 10.1158/0008-5472.CAN-08-3691. Epub 2009 Mar 10.

19.

Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer.

Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, Cooper LJ, Gelovani J, Hwu P.

Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14342-6. doi: 10.1073/pnas.0804105105. Epub 2008 Sep 15.

20.

The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells.

Symons HJ, Levy MY, Wang J, Zhou X, Zhou G, Cohen SE, Luznik L, Levitsky HI, Fuchs EJ.

Biol Blood Marrow Transplant. 2008 May;14(5):499-509. doi: 10.1016/j.bbmt.2008.02.013.

21.

Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.

Mirmonsef P, Tan G, Zhou G, Morino T, Noonan K, Borrello I, Levitsky HI.

Blood. 2008 Feb 15;111(4):2112-21. Epub 2007 Dec 6.

23.

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.

Zhou G, Drake CG, Levitsky HI.

Blood. 2006 Jan 15;107(2):628-36. Epub 2005 Sep 22.

24.

Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.

Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL.

J Exp Med. 2004 Dec 20;200(12):1581-92. Epub 2004 Dec 13.

25.

Role of LAG-3 in regulatory T cells.

Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA.

Immunity. 2004 Oct;21(4):503-13.

26.

Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.

Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello IM, Levitsky HI, Sotomayor EM.

Cancer Res. 2003 Dec 15;63(24):9007-15.

27.

Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.

Luznik L, Slansky JE, Jalla S, Borrello I, Levitsky HI, Pardoll DM, Fuchs EJ.

Blood. 2003 Feb 15;101(4):1645-52. Epub 2002 Oct 24.

28.

Tumor-specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines.

Housseau F, Langer DA, Oberholtzer SD, Moorthy A, Levitsky HI, Pardoll DM, Topalian SL.

Int J Cancer. 2002 Mar 1;98(1):57-62.

29.

New Developments in the Therapy of Acute Myelocytic Leukemia.

Gorin NC, Estey E, Jones RJ, Levitsky HI, Borrello I, Slavin S.

Hematology Am Soc Hematol Educ Program. 2000:69-89.

PMID:
11701536
30.
31.

Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy.

Wu B, Wu JM, Miagkov A, Adams RN, Levitsky HI, Drachman DB.

J Immunol. 2001 Apr 1;166(7):4773-9.

32.

When magic bullets miss their mark.

Levitsky HI.

Blood. 2001 Feb 15;97(4):833. No abstract available.

33.

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.

Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF.

Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72.

PMID:
10950151
34.

Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T-cell tolerance.

Levitsky HI.

Cancer J. 2000 May;6 Suppl 3:S281-90. Review. No abstract available.

PMID:
10874499
35.
36.

CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes.

Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky HI, Pardoll DM.

J Exp Med. 2000 Feb 7;191(3):541-50.

37.

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG.

Cancer Res. 1999 Oct 15;59(20):5160-8.

38.

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81.

39.
40.

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.

Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, Fein S, Schoenberger S, Levitsky HI.

Nat Med. 1999 Jul;5(7):780-7.

PMID:
10395323
41.

Chronic oxytocin pretreatment inhibits adenylyl cyclase activity in cultured rat myometrial cells.

Lindeman KS, Hirshman CA, Kuhl JS, Levitsky HI, Emala CW.

Biol Reprod. 1998 Nov;59(5):1108-15.

PMID:
9780316
42.

Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.

Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA.

J Immunol. 1998 Jan 15;160(2):643-51.

43.

Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.

Nigam A, Yacavone RF, Zahurak ML, Johns CM, Pardoll DM, Piantadosi S, Levitsky HI, Nelson WG.

Int J Oncol. 1998 Jan;12(1):161-70.

PMID:
9454900
44.

Accessories for naked DNA vaccines.

Levitsky HI.

Nat Biotechnol. 1997 Jul;15(7):619-20. No abstract available.

PMID:
9219258
45.

Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.

Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AH Jr, Piantadosi S, Dranoff G, Mulligan RC, Pardoll DM, Marshall FF.

Cancer Res. 1997 Apr 15;57(8):1537-46.

46.

Canarypox virus vectors for gene transfer in cancer immunotherapy.

Levitsky HI.

J Natl Cancer Inst. 1997 Mar 19;89(6):408-9. No abstract available.

PMID:
9091636
47.

The best cytokine for the job.

Levitsky HI.

Nat Med. 1997 Feb;3(2):126. No abstract available.

PMID:
9018223
48.

Tumors derived from antigen presenting cells.

Levitsky HI.

Semin Immunol. 1996 Oct;8(5):281-7. Review.

PMID:
8956456
49.

Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.

Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW.

J Immunol. 1996 May 15;156(10):3858-65.

PMID:
8621924
50.

Enhanced immune priming with spatial distribution of paracrine cytokine vaccines.

Jaffee EM, Thomas MC, Huang AY, Hauda KM, Levitsky HI, Pardoll DM.

J Immunother Emphasis Tumor Immunol. 1996 May;19(3):176-83.

PMID:
8811492

Supplemental Content

Loading ...
Support Center